Cited 24 time in
Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Shin, Seung Ho | - |
| dc.contributor.author | Lee, Ji Su | - |
| dc.contributor.author | Zhang, Jia-Min | - |
| dc.contributor.author | Choi, Sungbin | - |
| dc.contributor.author | Boskovic, Zarko, V | - |
| dc.contributor.author | Zhao, Ran | - |
| dc.contributor.author | Song, Mengqiu | - |
| dc.contributor.author | Wang, Rui | - |
| dc.contributor.author | Tian, Jie | - |
| dc.contributor.author | Lee, Mee-Hyun | - |
| dc.contributor.author | Kim, Jae Hwan | - |
| dc.contributor.author | Jeong, Minju | - |
| dc.contributor.author | Lee, Jung Hyun | - |
| dc.contributor.author | Petukhov, Michael | - |
| dc.contributor.author | Lee, Sam W. | - |
| dc.contributor.author | Kim, Sang Gyun | - |
| dc.contributor.author | Zou, Lee | - |
| dc.contributor.author | Byun, Sanguine | - |
| dc.date.accessioned | 2022-12-26T12:45:43Z | - |
| dc.date.available | 2022-12-26T12:45:43Z | - |
| dc.date.issued | 2020-07 | - |
| dc.identifier.issn | 2375-2548 | - |
| dc.identifier.issn | 2375-2548 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/6461 | - |
| dc.description.abstract | Despite considerable efforts, mTOR inhibitors have produced limited success in the clinic. To define the vulnerabilities of mTORC1-addicted cancer cells and to find previously unknown therapeutic targets, we investigated the mechanism of piperlongumine, a small molecule identified in a chemical library screen to specifically target cancer cells with a hyperactive mTORC1 phenotype. Sensitivity to piperlongumine was dependent on its ability to suppress RUVBL1/2-TTT, a complex involved in chromatin remodeling and DNA repair. Cancer cells with high mTORC1 activity are subjected to higher levels of DNA damage stress via c-Myc and displayed an increased dependency on RUVBL1/2 for survival and counteracting genotoxic stress. Examination of clinical cancer tissues also demonstrated that high mTORC1 activity was accompanied by high RUVBL2 expression. Our findings reveal a previously unknown role for RUVBL1/2 in cell survival, where it acts as a functional chaperone to mitigate stress levels induced in the mTORC1-Myc-DNA damage axis. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | AMER ASSOC ADVANCEMENT SCIENCE | - |
| dc.title | Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1126/sciadv.aay9131 | - |
| dc.identifier.scopusid | 2-s2.0-85089606706 | - |
| dc.identifier.wosid | 000556543100005 | - |
| dc.identifier.bibliographicCitation | SCIENCE ADVANCES, v.6, no.31 | - |
| dc.citation.title | SCIENCE ADVANCES | - |
| dc.citation.volume | 6 | - |
| dc.citation.number | 31 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
| dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
| dc.subject.keywordPlus | PHASE-II TRIAL | - |
| dc.subject.keywordPlus | DNA-PK | - |
| dc.subject.keywordPlus | GLIOBLASTOMA-MULTIFORME | - |
| dc.subject.keywordPlus | TEMSIROLIMUS CCI-779 | - |
| dc.subject.keywordPlus | MTOR | - |
| dc.subject.keywordPlus | ATM | - |
| dc.subject.keywordPlus | REPLICATION | - |
| dc.subject.keywordPlus | BIOGENESIS | - |
| dc.subject.keywordPlus | ONCOGENE | - |
| dc.subject.keywordPlus | THERAPY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
